Core Insights - FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for chronic diseases using fibroblasts and fibroblast-derived materials [1][6] - The company holds over 275 patents issued and pending, indicating a strong intellectual property portfolio [1][6] - A webinar is scheduled for July 10, 2025, where the CEO will discuss the company's fibroblast-based cell therapy platform and its potential applications [2][4] Company Overview - FibroBiologics aims to treat chronic, inflammatory, and degenerative conditions through an allogeneic fibroblast approach, which is scalable and cost-efficient [2] - The company's lead candidate, CYWC628, targets diabetic foot ulcers, with additional candidates aimed at multi-billion-dollar markets such as degenerative disc disease and multiple sclerosis [2] - The company is positioned as a next-generation leader in cell therapy and tissue regeneration [6] Upcoming Events - A live Q&A session will follow the webinar presentation, and a recording will be available on the company's investor section post-event [3] - Registration for the webinar is free, and questions can be submitted in advance [4]

Core Insights - FibroBiologics has appointed Jason D. Davis as Chief Financial Officer, bringing over 20 years of experience in public company finance and capital markets to support the company's growth [1][2][3] Company Overview - FibroBiologics is a clinical-stage biotechnology company focused on developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, holding over 275 patents issued and pending [1][7] - The company is advancing towards its Phase 1/2 clinical trial for diabetic foot ulcers scheduled for the second half of 2025 [2] Leadership and Experience - Jason D. Davis has a proven track record in leading companies through critical growth phases, including IPOs and capital raising initiatives, which is crucial for FibroBiologics as it moves its lead program into clinical trials [2][3] - Prior to joining FibroBiologics, Mr. Davis served as CFO of Virax Biolabs, where he successfully navigated the company through its IPO and managed multiple capital raises [4] Strategic Vision - Mr. Davis emphasized that FibroBiologics' fibroblast-based platform and strong intellectual property portfolio position the company as a high-growth, high-impact enterprise [4] - The company aims to deliver meaningful value not only for shareholders but also for patients globally [4]

Core Viewpoint - FibroBiologics is advancing its clinical-stage biotechnology efforts with plans to initiate a Phase 1/2 clinical trial for its fibroblast-based product candidate, CYWC628, aimed at treating diabetic foot ulcers in Australia by the third quarter of 2025 [1][4]. Recent Highlights - The company completed the CYWC628 master cell bank with Charles River, establishing a foundation for the upcoming clinical trial [4]. - A new patent was filed to enhance mitochondrial activity using the fibroblast platform, indicating a strategic move to strengthen competitive advantage [4]. - FibroBiologics presented at several investor and scientific conferences, enhancing visibility and interest in its platform [6]. Upcoming Milestones - The Phase 1/2 clinical trial for CYWC628 is set to begin in the third quarter of 2025, with completion expected in the first quarter of 2026 [6]. - Pre-clinical IND-enabling studies for the treatment of psoriasis with the fibroblast spheroid product candidate, CYPS317, are anticipated to be completed by the end of 2025 [6]. Financial Highlights - For the quarter ended March 31, 2025, research and development expenses were approximately $1.8 million, up from $1.0 million in the same period in 2024, primarily due to increased drug product expenses and hiring [7]. - General and administrative expenses rose to approximately $2.8 million from $2.5 million year-over-year, mainly due to additional personnel costs [8]. - The net loss for the quarter was approximately $5.0 million, a decrease from $8.5 million in the same period in 2024, attributed to changes in the fair value of the warrant liability [12].

Proprietary master cell bank of fibroblast-based spheroids product candidate, CYWC628, completed in accordance with Good Manufacturing Practices after successfully passing all required safety testing Preparations for Phase 1/2 clinical trial in Australia utilizing CYWC628 to treat diabetic foot ulcers are proceeding with plans to initiate in the second quarter of 2025 Cash and cash equivalents of approximately $14.0 million at December 31, 2024 HOUSTON, March 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc ...